---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-22-000056"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:13:38.005634+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Q1 net product revenue $21.9M (+33% pro forma); net loss $33.7M; reaffirms FY22 guidance

## Summary
- Q1 net product revenue $21.9M, up 33% pro forma vs prior year; net loss $33.7M ($0.25/share).
- Cash and investments $132.1M at quarter end; completed $100M draw on new $150M Hayfin term loan.
- Affirms 2022 guidance: revenue $105M-$120M, year-end cash $90M-$110M, cash flow breakeven by end-2023.
- Gvoke prescriptions topped 30,000 in Q1, retail TRx market share ~22%; launched Recorlev and Gvoke Kit.
- Entered $30M securities purchase agreement with Armistice Capital; issued ~10.2M shares and warrants.

## SEC filing metadata
- accession: 0001867096-22-000056
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000056/0001867096-22-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709622000056/xers-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-22-000056
- JSON: https://secwatch.observer/filing/0001867096-22-000056.json
- Plain text: https://secwatch.observer/filing/0001867096-22-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.